Recurrence in patients with clinically early-stage papillary thyroid carcinoma according to tumor size and surgical extent - 24/08/16
, Gyungyup Gong, M.D. b, Kyung-Ja Cho, M.D. b, Seung-Ho Choi, M.D. a, Soon Yuhl Nam, M.D. a, Sang Yoon Kim, M.D. aAbstract |
Background |
To investigate whether post-treatment recurrence differs by tumor size or surgical extent in clinically early-stage papillary thyroid carcinoma (PTC) patients.
Methods |
A total of 1,041 surgical patients with PTC 4 cm or less and no clinical evidence of metastases to regional or distant sites were included. Cox proportional hazard models were used to identify the clinicopathological variables predictive of post-treatment recurrence.
Results |
Central nodal involvement was found in 313 (34.1%) of 918 patients who underwent prophylactic central lymph node dissection. For the median follow-up of 83 months, 25 (2.4%) of 1,041 patients had a regional recurrence and 12 (1.2%) patients died of other causes. Male gender, tumor size, extranodal extension, and positive resection margin remained independent variables predictive of recurrence by multivariate analysis (P < .05 each). There was no significant impact of age (<45 vs ≥45 years, P = .944) or surgical extent (unilateral vs bilateral thyroidectomy, P = .776) on recurrence.
Conclusions |
Tumor size in patients with PTC of 4 cm or less is an important predictive factor for post-treatment recurrence.
Le texte complet de cet article est disponible en PDF.Highlights |
• | In a total 1,041 surgical patients with PTC ≤ 4 cm, factors predictive of recurrence were analyzed. |
• | Predictive factors were male, tumor size, extranodal extension, and positive resection margin. |
• | There was no significant impact of age or surgical extent on recurrence. |
• | Tumor size is an important predictive factor for recurrence |
Keywords : Papillary thyroid carcinoma, Surgery, Recurrence, Tumor size, Risk factor
Plan
| There were no relevant financial relationships or any sources of support in the form of grants, equipment, or drugs. |
|
| The authors declare no conflicts of interest. |
Vol 212 - N° 3
P. 419 - septembre 2016 Retour au numéro
Article précédent
- Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program
- Nathan M. Hinkle, James MacDonald, John P. Sharpe, Paxton Dickson, Jeremiah Deneve, Gitonga Munene
- Factors associated with 30-day unplanned pediatric surgical readmission
- Morgan K. Richards, David Yanez, Adam B. Goldin, Tim Grieb, Whitney M. Murphy, George T. Drugas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?